ClinicalTrials.gg
WithdrawnNCT01177852Updated Oct 19, 2016

Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis

A Phase 3 interventional study of diphenhydramine + dropropizine + pseudoephedrine and Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir). in Inflammation, Cough and Rhinitis, sponsored by Ache Laboratorios Farmaceuticos S.A.. Withdrawn. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2016-10-19.

Primary conditionCoughRegistry: InflammationReclassifiedWhy we changed it
Registry
Inflammation — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cough
Why
  1. Inflammation is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Cough.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
2 Years to 12 Years
Sex
All
01

Study summary

Multicenter clinical trial, phase III, controlled by active medicine, open, randomized, enroll 962 children, 2 to 12 years old, that suffer acute inflammation upper airway characterized by non-productive cough, daytime/nighttime, with duration for at least 3 and no more than 5 consecutive days (without systemic/topic use of medication during this period) followed by nasal congestion, with or without associate other nasal symptoms (sneezing, runny nose, nasal itching and/or mouth breathing). The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization.

02

Conditions studied

  • Inflammation
  • Cough
  • Rhinitis

Browse trials for

Keywords

  • cough, acute rhinitis, common cold, nasal symptoms, children.
  • Acute inflammation upper airway
03

In context

Cough Reclassified

428 studies on the registry are indexed under Cough; 68 are open to participants now.

Browse Cough studies →

Lead sponsor

Ache Laboratorios Farmaceuticos S.A. is the lead sponsor of 36 studies on the registry; 5 are open to participants now.

Compared within Cough, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammation. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
2 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients between 2 and 12 years old, of both sexes;
  2. Clinical condition compatible with acute rhinitis accompanied by nasal obstruction;
  3. Non-productive cough, daytime and/or nighttime with at least 3 and up 5 consecutive days in duration;
  4. Score greater than or equal to 3 points on the cough severity score (As per item 4.1.2);
  5. Score greater than or equal to 2 points on the nasal obstruction severity score (As per item 4.1.3);
  6. ICF signed by a parent/caregiver/representant;
  7. Parent/Caregiver/Representant capacity, according to investigator evaluation, for compliance at the treatment and protocol requirements, fulfilling the regular visits;

Exclusion criteria

Exclusion Criteria:

  1. Non-productive cough with purulent smear, fever (axillar temperature superior than 37,8°C/100°F), purulent runny nose and other signs and symptoms of bacteria infection of upper and lower airways at 7 days before the screening/randomization visit;
  2. Septal deviation level III (in any region and any nasal cavity) and/or nasal polyps or other determinants conditions of nasal congestion;
  3. Previous diagnosis of asthma;
  4. Patients under treatment for chronic allergy;
  5. Presence of purulent or mucopurulent secretion, nasal vault or mal formations (cleft lip or cleft nasolabial corrected or not) in nasal vestibule;
  6. Current use of systemic antibiotics for any reason;
  7. Use of prohibited medicine within the prescribed period before V0 as shown in item 9.3 of this protocol;
  8. Participation in last one year of clinical protocols;
  9. Any psychiatric diseases, including major depression;
  10. Presence of mental retardation from any cause;
  11. Diagnosis of renal or hepatic failure;
  12. History of to any component of the study drugs;
  13. Relatives of sponsor´s or study site´s employee;
  14. Current evidence of diseases: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, , pulmonary, or another disease that block the patient participation;
  15. Patient or parent/caregiver/representant with a history of lack of compliance to treatment or previous treatment protocols;
  16. Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Notuss® syrup

    Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).

    Drug: diphenhydramine + dropropizine + pseudoephedrine

  • Active comparator
    Dropropizine + Pseudoephedrine and brompheniramine

    Group 2: combined use of dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate.

    Drug: Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).

Interventions

  • Drugdiphenhydramine + dropropizine + pseudoephedrine

    Drug pages: Diphenhydramine · Dipropizine · Pseudoephedrine

    Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup). Posology: The medicine treat will be as follows: - Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml

  • DrugDropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).

    Dropropizine: Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml Pseudoephedrine hydrochloride + brompheniramine maleate: Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml

06

What researchers measure

Primary outcomes

  1. Improvement of nasal congestion and cough

    Participants were evaluated (by a parent/guardian/caregivers) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.

    Time frame: Evaluated on the day 2 after beginning treatment

Secondary outcomes

  1. Improvement of nasal congestion and cough

    Participants were evaluated (by a parent/guardian/caregivers) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.

    Time frame: Evaluated on the 7(±1) day after beginning treatment

  2. Improvement of non-obstructive nasal symptoms

    Participants were evaluated (by a parent/guardian/caregivers for pain intensity by using a sum of 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.

    Time frame: Evaluated on the day 2 and 7 (±1) after beginning treatment

  3. Reduction of the frequency of nighttime awakenings of parent/guardian/roommate of the child

    Time frame: Evaluated on the day 2 and 7 (±1) after beginning treatment

  4. Reduction of vomiting frequency episodes triggered by coughing

    Time frame: Evaluated on the day 2 and 7 (±1) after beginning treatment

  5. Improvement of acute rhinitis signs

    Assessed by anterior rhinoscopy and application of specific clinical scores

    Time frame: Evaluated on the day 2 and 7 (±1) after beginning treatment

  6. Use of rescue medication

    Time frame: Evaluated on the day 2 and 7 (±1) after beginning treatment

  7. Overall impression of improvement by the investigator

    Specific scale and overall impression of improvement by a parent/guardian/ caregiver of the child

    Time frame: Evaluated on the day 2 and 7 (±1) after beginning treatment

  8. Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.

    Collection of safety data throughout the whole study period

    Time frame: Will be evaluated during the 7(± 1) days of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011 and a primary completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2010
First posted
Aug 9, 2010
Start
Oct 2011
Primary completionEst.
Apr 2012
Last update
Oct 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01177852
First posted
Aug 9, 2010
Start date
Oct 2011
Primary completion
Apr 2012 (estimated)
Last update
Oct 19, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Diphenhydramine · Dipropizine · Pseudoephedrine

Start the discussion